Neurology Search
Neurology Neurology
meningitis%20-%20acute,%20bacterial
MENINGITIS - ACUTE, BACTERIAL

Acute meningitis is the infection of the subarachnoid space and cerebrospinal fluid by bacteria that may cause local and systemic inflammatory response.
There is the classic triad of symptoms of fever, neck stiffness and altered level of consciousness.
Other symptoms include chills, myalgia, photophobia, severe headache, focal neurologic symptoms, nausea, vomiting, seizures and some patients may present with rash.

 

Definition

  • Meningitis is the infection of the meninges and subarachnoid space that is usually caused by bacteria results in high mortality and morbidity throughout the world

Etiology

  • H influenza type B, N meningitidis and S pneumoniae 
  • Causative agents depend on the age of the patient and predisposing factors
  • The introduction of conjugated vaccines have caused decline in the incidence of bacterial meningitis in children thus majority of cases are now present in the adult population

Other causes of acute meningitis include the following:

  • Spirochetes eg Treponema pallidum
  • Mycobacteria eg Mycobacterium tuberculosis
  • Fungi eg Cryptococcus, Coccidioides, Sporothrix
  • Viruses eg herpes simplex virus (HSV), varicella zoster, cytomegalovirus (CMV), enterovirus
  • Protozoa and helminths

Signs and Symptoms

  • Classic triad: Fever, neck stiffness and an altered level of consciousness
  • Other symptoms:
    • Chills
    • Myalgia
    • Photophobia
    • Severe headache
    • Focal neurologic symptoms (eg cranial nerve palsies, ataxia, dilated/unequal and poorly reacting pupils - late sign)
    • Nausea/vomiting
    • Seizures (late sign)
    • Some patients may present with petechial rash
    • Some patients may not present with the classic signs (eg alcoholics, patients who are immunocompromised and who had meningitis after neurosurgery)
Editor's Recommendations
Most Read Articles
Repeat doses of intrathecal nusinersen safe in infantile-onset SMA
Elvira Manzano, 29 May 2018
Repeat doses of the intrathecal antisense oligonucleotide nusinersen in children with infantile-onset spinal muscular atrophy (SMA) continue to demonstrate safety, according to  early data from the phase III SHINE extension study, bringing considerable hope to the SMA community.
Combo regimen confers PFS advantage for glioblastoma
Audrey Abella, 29 Aug 2018
The combination of the alkylating nitrosourea compound lomustine and the monoclonal antibody bevacizumab prolonged progression-free survival (PFS) in patients with progressive glioblastoma compared with either drug alone, a meta-analysis has shown.
Original New Drug Application Approvals by US FDA (16 - 31 August 2018)
31 Aug 2018
New drug applications approved by US FDA as of 16 - 31 August 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Young people with ADHD more likely to have traumatic brain injury
29 Aug 2018
The risk of traumatic brain injury (TBI) is elevated in young people with attention-deficit/hyperactivity disorder (ADHD), though long-term ADHD medication can reduce this risk, a recent study has found.